NCT02271139
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02271139 |
| Title | Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib |
| Recruitment | No longer available |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Genentech, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
CKB BOOST